<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04046497</url>
  </required_header>
  <id_info>
    <org_study_id>19-0307-A</org_study_id>
    <nct_id>NCT04046497</nct_id>
  </id_info>
  <brief_title>Artificial Intelligence to Measure Adherence to Oral Medication</brief_title>
  <official_title>Early-phase Schizophrenia: Practice-based Research to Improve Outcomes (ESPRITO) - Using Artificial Intelligence to Measure Adherence to Oral Medication</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwell Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute of Mental Health (NIMH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwell Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of this project is to use an artificial intelligence (AI) smartphone app to provide&#xD;
      support for medication adherence by patients with first episode psychosis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The challenge of oral medication adherence in first-episode psychosis (as in any potentially&#xD;
      chronic illness) is enormous, and numerous studies have linked non-adherence to increased&#xD;
      rates of relapse/ hospitalization. Determining whether a patient is adhering to medication is&#xD;
      a challenge. Pill counts, pharmacy records, technology-assisted monitoring, biological&#xD;
      assays, and a range of self-report and interviewer-rated scales have been employed. In other&#xD;
      areas of medicine such as antiretroviral treatment Direct Observation of Treatment (DOT) has&#xD;
      been employed with excellent success both in monitoring and demonstrated improvement of&#xD;
      important clinical outcomes. DOT is clearly not feasible in community settings. An artificial&#xD;
      Intelligence (AI) platform that can be downloaded as an application onto a smart phone app&#xD;
      represents a novel approach to offering DOT to support participant oral medication adherence&#xD;
      and thereby improve outcomes. Aims of the project are: 1) to document acceptability to&#xD;
      patients of the AI smartphone app based upon participation in the study and 2) to compare&#xD;
      rates of hospitalization and emergency room visits between participants who receive the AI&#xD;
      smartphone app with participants who receive standard care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 20, 2020</start_date>
  <completion_date type="Anticipated">March 15, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Service Utilization Report Form</measure>
    <time_frame>12 months</time_frame>
    <description>Provides participant utilization of psychiatric ER visits or psychiatric hospitalization</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>First Episode Psychosis</condition>
  <arm_group>
    <arm_group_label>Smartphone App</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>artificial intelligence (AI) smartphone app to provide support for medication adherence</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Usual care provided at CSC clinic</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Smartphone App</intervention_name>
    <description>artificial intelligence (AI) smartphone app to provide support for medication adherence</description>
    <arm_group_label>Smartphone App</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual Care</intervention_name>
    <description>Usual Care provided by CSC clinic</description>
    <arm_group_label>Usual Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Enrolled in a CSC program&#xD;
&#xD;
          -  Prescribed an oral antipsychotic&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  none&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Patricia Marcy, BSN</last_name>
    <phone>347-439-8035</phone>
    <email>pmarcy@northwell.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cristina Gonzalez, MS</last_name>
    <phone>347-804-3605</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>InterAct</name>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacob Gonzalez</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>InterAct of Michigan</name>
      <address>
        <city>Kalamazoo</city>
        <state>Michigan</state>
        <zip>49007</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dana Schrader</last_name>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>July 1, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 6, 2019</study_first_posted>
  <last_update_submitted>December 4, 2020</last_update_submitted>
  <last_update_submitted_qc>December 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

